EyePoint, Inc. (FRA:PV3B)
Germany · Delayed Price · Currency is EUR 13.01
+0.33 (2.60%)
Last updated: Jan 28, 2026, 3:25 PM CET
EyePoint Employees
EyePoint had 165 employees as of December 31, 2024. The number of employees increased by 44 or 36.36% compared to the previous year.
Employees
165
Change (1Y)
44
Growth (1Y)
36.36%
Revenue / Employee
€218,700
Profits / Employee
€1,062,803
Market Cap
942.10M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 165 | 44 | 36.36% | 165 | 0 |
| Dec 31, 2023 | 121 | -23 | -15.97% | 121 | 0 |
| Dec 31, 2022 | 144 | 21 | 17.07% | 144 | 0 |
| Dec 31, 2021 | 123 | 22 | 21.78% | 122 | 1 |
| Dec 31, 2020 | 101 | 17 | 20.24% | 98 | 3 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Paul Hartmann AG | 10,082 |
| Gelsenwasser AG | 1,898 |
| FRoSTA Aktiengesellschaft | 1,760 |
| Maschinenfabrik Berthold Hermle AG | 1,603 |
| Südwestdeutsche Salzwerke AG | 1,186 |
| EUROKAI GmbH & Co. KGaA | 950 |
| tonies SE | 567 |
| Northern Data AG | 199 |
EyePoint News
- 5 weeks ago - EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know - Nasdaq
- 6 weeks ago - EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - EyePoint (EYPT) Grants Stock Options to New Employees as Inducement Awards - GuruFocus
- 6 weeks ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Cormorant Asset Management Reduces Stake in EyePoint Pharmaceuticals - GuruFocus
- 7 weeks ago - EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
- 2 months ago - EyePoint (EYPT) Receives Green Light to Proceed with Phase 3 DURAVYU Trials - GuruFocus
- 2 months ago - EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration - Wallstreet:Online